S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

DexCom (DXCM) Stock Price, News & Analysis

$115.32
-0.85 (-0.73%)
(As of 02/27/2024 ET)
Today's Range
$114.55
$116.42
50-Day Range
$115.32
$129.70
52-Week Range
$74.75
$139.55
Volume
2.27 million shs
Average Volume
3.20 million shs
Market Capitalization
$44.46 billion
P/E Ratio
88.03
Dividend Yield
N/A
Price Target
$134.64

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
16.8% Upside
$134.64 Price Target
Short Interest
Bearish
4.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.64mentions of DexCom in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$7.21 M Sold Last Quarter
Proj. Earnings Growth
26.44%
From $1.74 to $2.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Medical Sector

75th out of 944 stocks

Surgical & Medical Instruments Industry

13th out of 88 stocks


DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

Wall Street is surprisingly most bullish on these 3 Nasdaq stocks
Analysts are gradually shifting toward underperforming, less prominent names to find the next big thing - including these three current Wall Street faves
Wall Street is surprisingly most bullish on these 3 Nasdaq stocks
NVIDIA is the best example. After soaring 239% last year, the semiconductor leader is up almost 50% year-to-date.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
3 Nasdaq stocks likely to make big earnings splashes
Here we look at a few examples of high beta, high standard deviation Nasdaq-100 stocks that are poised to have volatile earnings moves in the near future.
DXCM Mar 2024 139.000 call
Validea Detailed Fundamental Analysis - DXCM
Dexcom Announces Upcoming Conference Presentation
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
DexCom (NASDAQ:DXCM) Sees Large Volume Increase
DXCM Jan 2026 140.000 call
DXCM Mar 2024 130.000 call
DXCM Mar 2024 121.000 call
DXCM Mar 2024 80.000 put
DXCM Mar 2024 114.000 call
DXCM Feb 2024 107.000 call
DexCom Inc EVP CFO Jereme Sylvain Sells Company Shares
Multiple Factors Pushed DexCom (DXCM) in Q4
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/28/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
9,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$134.64
High Stock Price Target
$151.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+16.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$541.50 million
Pretax Margin
19.61%

Debt

Sales & Book Value

Annual Sales
$3.62 billion
Cash Flow
$2.05 per share
Book Value
$5.35 per share

Miscellaneous

Free Float
383,934,000
Market Cap
$44.46 billion
Optionable
Optionable
Beta
1.20

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of DexCom was last updated on Sunday, February 25, 2024 at 3:21 PM.

Pros

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • DexCom, Inc. focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems, which are in high demand due to the increasing prevalence of diabetes.
  • The company has a strong track record of innovation and product development, staying ahead of competitors in the medical device industry.
  • Recent developments in DexCom's CGM technology have received positive feedback from endocrinologists, physicians, and diabetes educators, indicating a growing market acceptance.
  • DexCom's stock price has shown consistent growth in recent periods, reflecting investor confidence in the company's future prospects.
  • The company's direct-to-consumer approach allows for better market penetration and customer engagement, leading to higher sales and revenue.

Cons

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • While DexCom's CGM systems are innovative, they face competition from other medical device companies, which could impact market share and pricing.
  • The medical device industry is subject to regulatory changes and approvals, which could delay product launches and affect revenue streams.
  • Investing in DexCom, Inc. requires a thorough understanding of the healthcare sector and the specific challenges related to diabetes management, which may not be suitable for all investors.
  • Fluctuations in the healthcare market and insurance coverage for CGM devices could impact DexCom's sales and profitability in the future.
  • While the stock price has shown growth, it is important for investors to consider market volatility and potential risks associated with investing in a specific industry.














DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price target for 2024?

13 brokers have issued twelve-month price objectives for DexCom's stock. Their DXCM share price targets range from $100.00 to $151.00. On average, they expect the company's share price to reach $134.64 in the next year. This suggests a possible upside of 16.8% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2024?

DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM shares have decreased by 7.1% and is now trading at $115.32.
View the best growth stocks for 2024 here
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Thursday, February, 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.07. The medical device company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a trailing twelve-month return on equity of 28.31% and a net margin of 14.95%. DexCom's quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.53%), Baillie Gifford & Co. (4.28%), Capital Research Global Investors (3.97%), Sands Capital Management LLC (3.91%), Capital World Investors (2.41%) and Artisan Partners Limited Partnership (1.53%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 2/28/2024 by MarketBeat.com Staff